Navigation Links
Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
Date:3/30/2012

SAN DIEGO, March 30, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced the presentation of results from a post-hoc subgroup analysis of the company's two large Phase 3 trials which demonstrated that cancer patients with Clostridium difficile-associated diarrhea (CDAD) had higher clinical cure rates, better sustained response and lower recurrence when treated with DIFICID® (fidaxomicin) tablets compared to oral vancomycin. The data will be presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The analysis included 153 patients with active cancer who were treated in the two DIFICID Phase 3 studies and who received 8 days or more of treatment with DIFICID or oral vancomycin. In the overall combined population, patients with cancer had significantly lower cure and sustained response rates than patients without cancer. DIFICID was five times more likely than vancomycin to produce a clinical response and three times more likely to lead to a sustained response, while patients treated with vancomycin had a 2.6 fold greater risk of experiencing recurrence. Specifically, DIFICID provided superior response compared to vancomycin across all clinical endpoints studied: clinical response (97.3% vs. 87.5%, 95% CI 1.07-23.98; p=0.041), sustained response (83.6% vs. 61.3%, 95% CI 1.50-6.91; p=0.003) and disease recurrence (14.1% vs. 30.0%, 95% CI 0.16-0.89; p=0.025). Furthermore, cancer patients who were treated with DIFICID in the clinical studies had similar cure, recurrence and sustained response rates as non-cancer patients who received the drug, while cancer patients treated with vancomycin tended to have poorer outcomes than non-cancer patients. The ov
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results
2. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
3. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
4. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
5. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
8. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
9. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
10. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
11. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... GLENWOOD, Ill. , Aug. 22, 2014  Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... announced today that William E. Saxelby , its ... as President and Chief Executive Officer and as a ... September 15, 2014.  He will be replaced on an ...
(Date:8/21/2014)... GREENWICH, Conn. , Aug. 21, 2014 /PRNewswire/ ... West Lafayette, Indiana , has ... determination and characterization of small and large molecules, ... addition of the Bruker maXisPlus Q-TOF mass spectrometer. ... Jonathan Goldman , CEO, Aptuit, said, "The expanded ...
(Date:8/21/2014)... Aug. 21, 2014 Nektar Therapeutics (NASDAQ: ... today announced positive results from its Phase 3 ... extended half-life recombinant factor VIII (rFVIII) treatment for ... which met its primary endpoint in reducing annualized ... to the on-demand arm. Top-line results ...
Breaking Medicine Technology:Landauer, Inc. Announces Executive Management Change 2Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... A placebo controlled study involving top ice ... reaction times reduced by one fifth in players using the ... were given 12 minutes of bright light via the ear ... by the Department of Exercise and Medical Physiology at Verve ...
...   SA Health , the public health system of South ... it signed the final agreement to deploy the Sunrise ... solutions from Allscripts (NASDAQ: MDRX ) ... hospitals and health clinics serve a population of 1.6 million ...
Cached Medicine Technology:Bright Light Therapy via Ear Canals Improved Reaction Times of Top Athletes in a Placebo-Controlled Psycho-Motoric Study 2Australia's SA Health Finalizes Allscripts Agreement 2Australia's SA Health Finalizes Allscripts Agreement 3Australia's SA Health Finalizes Allscripts Agreement 4
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... Pakulski that uses university-proven research to show people how they ... of lean muscle in only a matter of weeks has ... , “Ben Pakulski is one of the most well-known ... to get the body he has today, that in itself ...
(Date:8/22/2014)... the first time an oncogenic somatic mutation at amino ... has been identified in small cell lung cancer (SCLC) ... cell lines produced increased intracellular signaling and cell growth. ... cancer representing 15% of all lung cancers and is ... lung cancer, has been extensively examined for genomic alterations ...
(Date:8/22/2014)... (RA), a complex autoimmune disease that affects 1 ... not only cope with pain, disability and joint ... work, family life and marital functioning. While many ... and disability is common. In addition, some patients ... or side effects. Because of this, there is ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... Dr. Sen and Dr. Samantha Pearson to help people ... and avoid corrective vision surgery by instead improving their ... prompting an investigative review. , “There’s a reason ... dollars in revenue each year—it’s because people just assume ...
(Date:8/22/2014)... 22, 2014 Testosterone treatment lawsuits ... U.S. courts on behalf of men who allegedly ... of prescription low testosterone therapies, Bernstein Liebhard LLP ... was filed against Pfizer Inc. on July 31st ... heart issues due to his use of Depo-Testosterone. ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4
... for Prevention, Mental,Health and Low-Income Programs, Boosted ... Today a minority of,the U.S. Senate ... for the 44 million Americans who depend ... Providers Act, which would have improved,Medicare,s prevention, ...
... Would Have Improved Benefits for Prevention, Mental,Health and ... FE, N.M., June 12 SUMMARY: Today a,minority ... protect and,improve Medicare for the 44 million Americans ... and Providers Act, which would have,improved Medicare,s prevention, ...
... Corporation,(Nasdaq: PODD ), the leader in patch ... announced the Company will participate in,the William Blair ... scheduled to present an overview of the Company ... The Four Seasons Hotel in Chicago, IL., ...
... 12 Benchmark findings from the,study, conducted ... (BEB),suggest that formal management of training program ... one of the key success drivers in,effective ... Download a complimentary excerpt of this member-driven ...
... Senate voted 54,to 39 in favor of S. ... of 2008. However, that did not achieve the ... provisions that provide,prompt payment of Medicare Part D ... reimbursement cuts for generic prescription,drugs. In response Bruce ...
... complaints of insomnia predicted a healthier life, study finds ... is associated with healthy aging, a new study found. ... assessed 2,226 women aged 60 and older for use ... awakening, snoring, overall sleep quality, and sleep duration. Based ...
Cached Medicine News:Health News:AARP Indiana Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP Indiana Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:AARP NEW MEXICO KEY VOTE NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP NEW MEXICO KEY VOTE NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:Better Sleepers Are 'Successful Agers' 2
... of DOA Panel Test is ... in vitro test. It is ... substances in human urine specimens. ... in the point of care ...
... a qualitative immunoassay intended to ... usage of cocaine by detecting ... in human urine at a ... It is for health care,professional ...
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... delivers performance, value and safety ... smaller laboratories. It's an affordable, ... small sample volume in both ... a wide operating range and ...
Medicine Products: